
Not just humans, even ants follow caste. It defines their destiny
Using the clonal raider ant, Ooceraea biroi, which allows precise control of genetics and rearing conditions, the team found that size and caste are inextricably linked—but not by environment alone.
The destiny is an interplay between genes, body size, environment. (Photo: Pixabay)
Queens aren't just large workers; they possess wings, large ovaries, and special eyes, while workers lack these features. By manipulating food, temperature, and caregiver genotypes, the team found that these environmental factors influenced caste only by altering the ants' final body size, smaller ants remained workers, while those that grew big enough developed queen-like features.But intriguing differences emerged when the team studied ants from different genetic lines under identical conditions. Some genetic lines produced ants that, even at small sizes, were more likely to develop queen-like traits."Genes don't just influence how big an ant grows," says Patrick Piekarski, co-author and postdoctoral researcher in Kronauer's lab, "they also set the body size threshold at which queen features appear."In other words, two ants of the same size but different genetics can have drastically different chances of becoming queens.
Researchers set out to untangle whether environment or genetics is more important. (Photo: Getty)
While environmental factors, like access to food, can increase or decrease overall size, only genetics determine how size translates to caste. The findings highlight that ant societies have evolved a robust, genetically controlled system for dividing roles, with genes both shaping growth and defining what that growth means to the colony.Understanding the links between genes, size, and social roles isn't just about morphology, it's a window into the evolutionary logic behind insect societies and the roles individuals play within them.- EndsTrending Reel

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Hindustan Times
3 hours ago
- Hindustan Times
How India's biopharma industry is tackling the world's next health challenges
India has established itself as the pharmacy of the world. Supplying nearly 20% of the global generics market and 60% of the vaccine market, the country has established a strong foundation for affordable, large-scale pharmaceutical production. However, as global health challenges evolve, from infectious outbreaks to chronic lifestyle diseases, India's approach must also adapt. With non-communicable diseases like cardiovascular issues, diabetes, and others now making up over 70% of global deaths, the focus shifts from just volume to precision. If India wishes to maintain its global leadership and meet its ambitious goal of reaching a $300 billion biopharmaceutical industry by 2030, it must embrace next-generation therapies, such as gene therapies, antibody-drug conjugates (ADCs), and personalised medicine. Pharma(Pixabay/Representative) Fortunately, India, with its scientific talent, robust infrastructure, and exceptional population diversity, might be the launchpad the world needs. A significant milestone in India's biotech journey came in October 2023, when the CDSCO approved the country's first homegrown CAR-T cell therapy, NexCAR19. Developed entirely in India, this therapy for leukaemia and lymphoma showed response rates comparable to global CAR-T treatments. What sets it apart is the fact that it's being made available at a fraction of the typical price, making it a landmark in affordable, advanced immuno-oncology and India's first indigenously developed gene therapy. India is also making strides in antibody-drug conjugates (ADCs), that is, targeted cancer drugs that combine antibodies with potent toxins. Human trials for the first India-developed ADC candidate began in 2024. Meanwhile, the private sector is investing heavily in ADC manufacturing infrastructure. This comes at the right time: the global ADC market is expected to hit $23 billion by 2030, and India is positioning itself as a competitive, low-cost developer in this high-growth space. When it comes to precision medicine, India offers a uniquely rich landscape. With 1.4 billion people spanning diverse genetic, ethnic, and environmental backgrounds, it provides an ideal setting for testing and refining personalised therapies. The country also faces a dual burden of disease: persistent infectious threats like tuberculosis, accounting for 26–27% of global cases, alongside a rising tide of non-communicable diseases like diabetes and cardiovascular diseases. This diversity creates a robust, varied patient pool for clinical trials and real-world evidence studies. It's exactly what precision medicine needs: treatments that work not just in ideal conditions but in complex, real-world settings. Geographic and climatic variation, from the Himalayas to the coastal tropics, further adds to India's advantage. Significant strides in these arenas have been made possible due to active policy impetus. A cornerstone of India's biopharma push is the National Biopharma Mission, backed by ~$250 million from Indian and World Bank support. It enabled the country's first CAR-T trials and established a GMP-grade viral vector facility, fostering industry-academia collaboration and seeding a thriving biotech startup ecosystem. The government's ₹15,000 crore PLI scheme for the pharmaceutical industry is driving domestic production of complex biologics, vaccines, and high-value drugs. Covering 68 biopharma products and 157 priority drugs, it has approved 55 projects and already catalyzed over ₹30,600 crore in investment and ₹1.83 lakh crore in output by September 2024. The initiative aims to reduce India's import dependence and position the country as a global hub for advanced pharmaceutical manufacturing. The Ayushman Bharat Digital Mission is building a rich, anonymised health data backbone, enabling real-world evidence and post-market surveillance, and laying the foundation for precision medicine at a population scale. As DBT notes, India's genomic diversity is as varied as its culture or cuisine. Leveraging this scientifically will help address diseases that disproportionately affect Indian and developing-country populations. To this end, India is already scaling its genomic science to the population level. The Genome India Project has already sequenced 10,000 genomes from 83 ethno-linguistic groups and, as of January 2025, made this dataset publicly available. The government now targets 10 million genomes, supported by allied programs like CSIR's IndiGen and ICMR's National Genomics Core, which together are building reference variants for Indian populations. This genomic trove, paired with extensive patient registries, positions the country as a future hub for precision medicine and pharmacogenomics tailored to its uniquely diverse population. Despite strong momentum, India's biopharma industry must address a few critical roadblocks to realise its potential in advanced therapeutics fully. First, the regulatory framework needs to be strengthened. While CDSCO has deep experience with generics and vaccines, clear pathways for novel biologics, gene therapies, and precision medicine are still evolving. To this end, India must develop science-led, globally aligned regulatory guidelines with dedicated review pathways for advanced therapies, similar to the US FDA's breakthrough designation. Second, funding for innovation remains a bottleneck. Between 2013 and 2022, Indian biotech firms raised just $5 billion in venture capital, compared to $57 billion by U.S. biotech companies in 2023 alone. The government has tried to fill this gap through BIRAC grants and incubators and has recently proposed a Research-Linked Incentive (RLI) scheme to reward private R&D investments. Third, there is a talent shortage in high-end biopharma R&D and biomanufacturing. India's biopharma talent resilience score dropped from 6.3 in 2021 to 5.6 in 2023, and nearly half of pharma executives report difficulty hiring for critical roles. There is an immediate need to invest in specialised skill development programs for biologics, data science, and regulatory science to bridge this gap. Dr Tedros Adhanom Ghebreyesus, Director-General of the WHO, once said: 'Health is a human right. No one should get sick or die just because they are poor or because they cannot access the care they need.' India has the potential to turn that principle into practice by making the next generation of therapies not only practical but also accessible and affordable. If it succeeds, India won't just lead the biopharma race; it will redefine who gets to benefit from the future of medicine. This article is authored by Ankush Kapoor, co-founder and CEO, PharmNXT Biotech.


Hindustan Times
a day ago
- Hindustan Times
New study reveals the date the universe will die. It's sooner than you think
Amid multiple theories about the future of our universe, new data have surprised scientists, suggesting that the universe might stop expanding and ultimately collapse sooner than expected. During the past year, the study of various galaxies by the Dark Energy Survey (DES), as well as the Dark Energy Spectroscopic Instrument (DESI), has unveiled data that made cosmologists suggest that the universe might collapse in a 'Big Crunch,' reported. Universe to die in 33 billion years? DES and DESI unveiled data which suggest that the universe might collapse in a Big Crunch(Representative Image/ Pixabay) {{^userSubscribed}} {{^usCountry}} {{/usCountry}} {{#usCountry}} {{/usCountry}} {{/userSubscribed}} {{^userSubscribed}} {{^usCountry}} {{/usCountry}} {{#usCountry}} {{/usCountry}} {{/userSubscribed}} DES and DESI data reveal that the phenomenon, named dark energy, the force which accelerates the expansion of the universe, could be changing with time. This observation could result in a paradigm shift, meaning that the cosmological constant - the model of dark energy - could be flawed. {{^usCountry}} {{/usCountry}} The latest data has offered room for exploring radical new theories of the cosmos. A new study, which was presented in a paper in June and awaits peer review, has proposed a complex model for dark energy. Also Read: Violent Collision of Two Black Holes Rippled Across the Universe What does new study say about universe? {{^userSubscribed}} {{^usCountry}} {{/usCountry}} {{#usCountry}} {{/usCountry}} {{/userSubscribed}} {{^userSubscribed}} {{^usCountry}} {{/usCountry}} {{#usCountry}} {{/usCountry}} {{/userSubscribed}} {{^usCountry}} It suggests that two components contribute to dark energy, including the axion and cosmological constant. Axion: According to this hypothetical ultralight particle rarely interacts with matter. Such particles hold the ability to soak the entire universe. {{/usCountry}} {{#usCountry}} It suggests that two components contribute to dark energy, including the axion and cosmological constant. Axion: According to this hypothetical ultralight particle rarely interacts with matter. Such particles hold the ability to soak the entire universe. {{/usCountry}} Read More {{^usCountry}} Cosmological constant: It is a bare number mentioned in Einstein's theory of general relativity. The latest analysis notes that cosmological constant holds lower value, since part of the accelerated expansion could be attributed to axions. {{/usCountry}} {{#usCountry}} Cosmological constant: It is a bare number mentioned in Einstein's theory of general relativity. The latest analysis notes that cosmological constant holds lower value, since part of the accelerated expansion could be attributed to axions. {{/usCountry}} {{^usCountry}} The researchers involved in the study believe that a proper way to fit the DES and DESI data was to get axions working out with a negative cosmological constant. According to them, this suggests that we are living in a temporary period of accelerated expansion, which is heavily driven by the axion field. {{/usCountry}} {{#usCountry}} The researchers involved in the study believe that a proper way to fit the DES and DESI data was to get axions working out with a negative cosmological constant. According to them, this suggests that we are living in a temporary period of accelerated expansion, which is heavily driven by the axion field. {{/usCountry}} {{^userSubscribed}} {{^usCountry}} {{/usCountry}} {{#usCountry}} {{/usCountry}} {{/userSubscribed}} {{^userSubscribed}} {{^usCountry}} {{/usCountry}} {{#usCountry}} {{/usCountry}} {{/userSubscribed}} With time, axions will go on to dilute and lose steam. Later on, it will pave the way for the negative cosmological constant to take over, the study claims. Also Read: 'Dark universe detective' telescope releases first data. See pics The negative cosmological constant performs the opposite of a positive one and goes on to decelerate the expansion rate of our universe. This means, the cosmos expansion might slow down in future and start to reverse, resulting in a new "Big Crunch" phase. In the end process, the galaxies would merge with each other, while our universe might become smaller, hotter and denser, read the study. {{^userSubscribed}} {{^usCountry}} {{/usCountry}} {{#usCountry}} {{/usCountry}} {{/userSubscribed}} {{^userSubscribed}} {{^usCountry}} {{/usCountry}} {{#usCountry}} {{/usCountry}} {{/userSubscribed}} As per the predictions, the beginning of the end could be in about 10 billion years, which is too less compared with the present age of the universe. Another 10 billion years would be required for the cosmos to collapse. Ultimately, the universe could reach the final singularity state after more than 33 billion years of its total lifetime. FAQs: 1. What do astronomers calculate? In the latest study, they have studied new data from the Dark Energy Survey and the Dark Energy Spectroscopic Instrument. 2. What math do astronomers use? Astronomers take into consideration a wide range of mathematical concepts, such as algebra, calculus, probability and others. 3. What math is used by astronomers to measure distances in space? This is done through the cosmic distance ladder. {{^userSubscribed}} {{^usCountry}} {{/usCountry}} {{#usCountry}} {{/usCountry}} {{/userSubscribed}} {{^userSubscribed}} {{^usCountry}} {{/usCountry}} {{#usCountry}} {{/usCountry}} {{/userSubscribed}} trends united states See Less SHARE THIS ARTICLE ON
&w=3840&q=100)

First Post
2 days ago
- First Post
How a baby girl in Sweden grew a ‘micropenis' from lying on her father's chest
A 10-month-old baby girl in Sweden developed a 'micropenis' after she frequently lay on her father's bare chest, who applied a strong testosterone gel as part of a hormonal treatment. The baby soon began to show unexpected physical changes, which triggered panic among the parents. Here's what we know read more The 10-month-old baby girl in Sweden would often lie on her father's bare chest, a common skin-to-skin practice known to support early development and strengthen the parent-child connection. AI-generated representative image As bizarre as it sounds, a 10-month-old baby girl in Sweden started developing a 'micro-penis', all because she often lay on her father's bare chest, who had applied testosterone gel. And this isn't an isolated case. A Swedish doctor now says she's seen many similar cases, where young children showed unexpected physical changes after being exposed to hormone creams used by adults around them. Here's what happened, and what you should know to keep your child safe. How a baby girl developed a 'micropenis' In what started as a loving bonding routine, a 10-month-old baby girl in Sweden would often lie on her father's bare chest, a common skin-to-skin practice known to support early development and strengthen the parent-child connection. But what her parents didn't know was that her father had been regularly applying testosterone gel on his chest, a treatment typically prescribed to men with low testosterone levels. STORY CONTINUES BELOW THIS AD Without realising the risks, this repeated skin contact exposed the infant to high levels of the hormone, leading to unexpected and alarming changes in her genitalia. Over time, her parents noticed that her clitoris had begun to elongate, taking on a penis-like shape, while her labia started to fuse together, resembling a small scrotum. These changes were described as resembling a 'micropenis', which is usually reserved for underdeveloped male genitalia. Panicked, the family sought medical help. Blood tests quickly pointed to the cause. Secondary exposure to testosterone gel in children can trigger adverse effects such as premature puberty. Image for Representation. Pixabay 'I don't think people always understand how potent these treatments are,' said Professor Jovanna Dahlgren, a paediatric endocrinologist at Sahlgrenska University Hospital, speaking to local media channel Göteborgs-Posten. 'The parents become completely desperate when they understand what has happened,' she added. This particular case happened eight years ago, but it's far from isolated. Professor Dahlgren said she's treated at least half a dozen similar cases, all involving hormone creams or gels unintentionally transferred to children through skin contact with a parent. STORY CONTINUES BELOW THIS AD In another incident, she said, a 10-year-old boy developed breast tissue after unknowingly coming into contact with his mother's estrogen cream. Fortunately, in the Swedish girl's case, her symptoms began to reverse once her father stopped using the gel and skin-to-skin contact was avoided. How hormone creams can harm kids Doctors have been raising concerns after seeing multiple cases of children affected by accidental exposure to hormone creams, a danger many parents simply aren't aware of. These creams and gels are commonly prescribed to men with hypogonadism, a condition where the body doesn't produce enough sex hormones. While hypogonadism can affect men at any age, research suggests it becomes more common with age, impacting around 40 per cent of men over 45 and nearly half of those in their 80s. Testosterone replacement therapy (TRT) is often used to help with symptoms like low libido, erectile dysfunction, fatigue, mood changes, and muscle loss. These creams and gels are commonly prescribed to men with hypogonadism, a condition where the body doesn't produce enough sex hormones. Image for Representation. Pixabay However, problems arise when the gel isn't handled properly. If adults don't wash their hands, allow the gel to dry fully, or cover the application site, and then come into close contact with children, the hormone can be absorbed through the child's skin. Even small amounts can cause physical changes, including signs of early puberty or virilisation. STORY CONTINUES BELOW THIS AD Experts strongly advise users to apply the gel only to specified areas like the shoulders, upper arms, or abdomen, let it air-dry completely before getting dressed, wash hands thoroughly afterwards, and keep the area covered. Most importantly, health officials stress that skin-to-skin contact with children, especially babies, should be strictly avoided for several hours after applying the medication. With input from agencies